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After the first description of Brugada syndrome [1] and its genetic mutation in SCN5A gene 
[2],  the  understanding  of  this,  often  fatal,  genetic  abnormality  has  greatly  increased. 
Electrophysiologically,  ventricular  myocardium  is  composed  of  three  distinct  cell  types, 
namely epicardial,  endocardial,  and M cells [3]. Action potentials recorded from epicardial 
and M cells display a spike-and-dome morphology, because of prominent transient outward 
current-mediated  phase  1,  which  is  not  prominent  in  the  endocardial  cells.  In  Brugada 
syndrome, different genetic mutations in the SCN5A gene, which encodes for the α subunit of 
the cardiac sodium channel, causes a loss of function in the INa channel, resulting in a loss of 
the action potential dome in epicardial myocytes. Accentuated Ito-mediated action potential 
notch and the loss of action potential dome in the epicardium, but not endocardium of the right 
ventricular outflow tract, gives rise to a transmural voltage gradient. This causes ST segment 
elevation in leads V1 - V3 and induction of ventricular fibrillation (VF) due to phase 2 reentry 
[4-8].
Agents that reduce outward currents (e.g. Ito, IK-ATP, IKs, IKr) or boost inward currents (e.g. 
ICa-L) at the end of phase 1 of AP can attenuate ST segment elevation and suppress episodes of 
ventricular arrhythmia. Such agents are candidates for a pharmacological approach to therapy 
of  the  Brugada  syndrome  [9].  In  right  ventricular  wedge  preparations  [6,8],  exposure  to 
pinacidil (potassium channel opener); a combination of pilsicainide (class IC sodium channel 
blocker)  and  terfenadine  (ICa-L blocker);  and  acetylcholine,  a  parasympathetic  agonist 
(blocking  effect  of  ICa-L),  produces  a  transmural  voltage  gradient  between  epicardial  and 
endocardial  cells  and  ST segment  elevation.  Isoproterenol  (β-adrenergic  agonist)  strongly 
augments ICa-L and restores the epicardial dome thus decreasing the ST segment elevation. Ito 
blockers like 4-aminopyridine (relatively selective), tedisamil, and quinidine (less selective), 
also restore the epicardial dome and decrease phase 1 action potential notch, thus decreasing 
ST segment elevation. In experimental settings the episodes of ventricular arrhythmia induced, 
were shown to be successfully suppressed by Ito blockade [6,8].                             
Based on the cellular  mechanism responsible for Brugada phenotype,  a cardio-selective Ito 
blocker  would  be  an  ideal  pharmaceutical  approach.  Efficacy  of  drugs  in  patients  with 
Brugada syndrome to prevent ventricular arrhythmia [9-20], especially  quinidine, as  reported 
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by Stelios  P et  al  in  this  journal  [21],  has  been well  documented  in  literature.  Quinidine 
decreases the transmural dispersion by blocking repolarizing currents, specifically Ito channel, 
and hence has shown to be clinically effective in episodes of ventricular storm [9-10] along 
with isoproterenol [9]. Denopamine (oral adrenergic stimulant) and atropine (anti-cholinergic 
agent) increases ICa-L and are also shown to be effective [11]. Cilostazol, a phosphodiesterase 
III inhibitor,  also has shown to reduce ST segment elevation,  probably due to its effect to 
increase  ICa-L and  heart  rate  [12].                                            
Hermida et al [16] also showed that hydroquinidine therapy prevented ventricular tachycardia 
(VT)/VF  inducibility  in  76%  of  asymptomatic  patients  with  Brugada  syndrome  on 
electrophysiology study, as well as VT/VF recurrence in all patients with multiple ICD shocks 
and  led  the  authors  to  suggest  that  preventive  treatment  by  hydroquinidine  may  be  an 
alternative  strategy  to  implantable  cardiac  defibrillator  (ICD)  placement  in  asymptomatic 
patients with Brugada syndrome and inducible arrhythmia. In another study by Belhassen et al 
[17], class IA drugs, especially quinidine, effectively prevented induction of VT/VF in 96% 
patients. In their study of 23 patients treated with these medications, no patient died or had a 
sustained ventricular arrhythmia during a mean follow-up period of 9.1 +/- 5.6 years (7 to 20 
years  in  15  patients)  which  suggested  that  EP-guided  therapy,  with  Class  IA  agents  is  a 
reasonable,  safe,  and  effective  approach  for  the  long-term  management  of  patients  with 
idiopathic  VF.                                              
With increasing utilization of non-drug approaches in Brugada syndrome, such as ICD's and 
ablation therapy [20], use of antiarrhythmic drugs has not been uniformly recommended and 
there  exists  no  large  randomized  prospective  studies  of  effectiveness  of  drugs,  especially 
quinidine, in patients having Brugada syndrome with/without ICD's. However, quinidine is the 
only  oral  antiarrhythmic  agent,  which  consistently  seems  to  be  effective  in  treatment  of 
ventricular  arrhythmia  related  to  Brugada  syndrome  [18-20].  However,  quinidine  as  an 
antiarrhythmic  drug,  is  not  very popular  as  it  requires  frequent  dosing,  is  associated  with 
frequent side effects and is not considered as effective as other class III antiarrhythmic agents. 
Hence the availability of quinidine decreased, as manufacturers found the drug production and 
marketing non-viable and stopped manufacturing them [22]. Orphan-drug status is intended 
for drugs that treat fewer patients, and the company, on its development is not expected to 
recover the cost of developing and marketing the drug, but needs to invest, due to social and 
political  responsibilities.  Quinidine  doesn't  even  fit  into  this  category,  as  it  is  already  a 
developed  drug.                                              
Although quinidine is one of the oldest drugs, there has been renewed interest in quinidine, for 
its  effectiveness  in  treating  ventricular  arrhythmia  related  to  Brugada syndrome,  and with 
fewer options available till the time a specific Ito blocker is available for clinical use, quinidine 
will  continue  to have a role in modern cardiology.  Hence,  drug manufacturing  companies 
should take social responsibility, and make this "endangered species" drug, easily available 
[21,22].
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